BR112022012246A2 - Uso de lemborexant para tratar insônia - Google Patents

Uso de lemborexant para tratar insônia

Info

Publication number
BR112022012246A2
BR112022012246A2 BR112022012246A BR112022012246A BR112022012246A2 BR 112022012246 A2 BR112022012246 A2 BR 112022012246A2 BR 112022012246 A BR112022012246 A BR 112022012246A BR 112022012246 A BR112022012246 A BR 112022012246A BR 112022012246 A2 BR112022012246 A2 BR 112022012246A2
Authority
BR
Brazil
Prior art keywords
lemborexant
pharmaceutically acceptable
acceptable salt
dose
child
Prior art date
Application number
BR112022012246A
Other languages
English (en)
Portuguese (pt)
Inventor
Satlin Andrew
Moline Margaret
Landry Ishani
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112022012246A2 publication Critical patent/BR112022012246A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112022012246A 2019-12-20 2020-12-18 Uso de lemborexant para tratar insônia BR112022012246A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Publications (1)

Publication Number Publication Date
BR112022012246A2 true BR112022012246A2 (pt) 2022-08-30

Family

ID=74191874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012246A BR112022012246A2 (pt) 2019-12-20 2020-12-18 Uso de lemborexant para tratar insônia

Country Status (11)

Country Link
US (1) US20230051268A1 (https=)
EP (1) EP4076463A1 (https=)
JP (2) JP2023508011A (https=)
KR (1) KR20220119065A (https=)
CN (1) CN115003305A (https=)
AU (1) AU2020408557A1 (https=)
BR (1) BR112022012246A2 (https=)
CA (1) CA3165481A1 (https=)
MX (1) MX2022007304A (https=)
TW (1) TW202137986A (https=)
WO (1) WO2021127359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024305901A1 (en) * 2023-06-29 2026-02-12 Janssen Pharmaceutica Nv Method of treating depression using seltorexant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
BR112014019909B1 (pt) 2012-02-17 2020-01-28 Eisai R&D Man Co Ltd processo para produção de compostos úteis como antagonistas do receptor de orexina-2
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors

Also Published As

Publication number Publication date
CN115003305A (zh) 2022-09-02
JP2025160480A (ja) 2025-10-22
EP4076463A1 (en) 2022-10-26
TW202137986A (zh) 2021-10-16
JP2023508011A (ja) 2023-02-28
CA3165481A1 (en) 2021-06-24
WO2021127359A1 (en) 2021-06-24
KR20220119065A (ko) 2022-08-26
MX2022007304A (es) 2022-08-22
AU2020408557A1 (en) 2022-08-11
US20230051268A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112014010417A2 (pt) Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
BR112018068784A2 (pt) método para o tratamento de leucemia
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
BR112019002513A2 (pt) uso e dosagem de agentes terapêuticos para endometriose
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112019002461A2 (pt) regime de dosagem para tratamento de tumores sólidos
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
CO2019003808A2 (es) Composición farmacéutica que comprende antagonista receptor de mineralocorticoides y uso de la misma
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
BR112015012497A2 (pt) combinações farmacêuticas
BR112022012246A2 (pt) Uso de lemborexant para tratar insônia
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
AR080048A1 (es) Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib
BR112022003419A2 (pt) Forma de dosagem oral sólida compreendendo naproxeno e vitamina b12
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
BR112016024510A2 (pt) ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.23 NA RPI NO 2865 DE 02/12/2025 POR TER SIDO INDEVIDA.

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]